GENE ONLINE|News &
Opinion
Blog

2024-01-04| R&DTechnology

Revolutionary Wristband Sensor Technology Predicts Alzheimer’s Risk

by Sinead Huang
Share To

Japanese researchers at Oita University and pharmaceutical company Eisai Co., Ltd. have achieved a milestone in Alzheimer’s disease (AD) research. They’ve unveiled the world’s first machine learning model designed to predict the accumulation of amyloid beta (Aβ) in the brain, a crucial indicator of AD. What makes this development extraordinary is the utilization of a wristband sensor, allowing for non-invasive and convenient data collection.

Innovative Integration of Biological and Lifestyle Data

Unlike previous studies focusing on cognitive tests, blood tests, and brain imaging, this research uniquely incorporates “biological data” and “lifestyle data” to predict brain Aβ accumulation. By integrating information from wristband sensors, including physical activity, sleep patterns, and heart rate, with lifestyle data gathered through medical consultations, such as daily routines and background information, the model achieves a comprehensive understanding of an individual’s risk factors.

The study, detailed in the online edition of Alzheimer’s Research & Therapy, involved a cohort of elderly individuals without dementia. Over a three-year period, 122 participants with mild cognitive impairment wore wristband sensors, providing continuous data. The machine learning model, incorporating support vector machine, Elastic Net, and logistic regression, demonstrated an impressive Area Under the Curve (AUC) of 0.79. This suggests the model’s effectiveness in predicting amyloid positivity, offering an accessible and cost-effective screening method.

Implications for Alzheimer’s Research and Future Developments

The implications of this research extend beyond the immediate breakthrough. With Alzheimer’s prevalence rising, especially in aging societies like Japan, the development of predictive tools becomes increasingly crucial. The newly developed model not only offers a less invasive alternative to existing detection methods but also presents an opportunity to identify individuals with pre-symptomatic mild cognitive impairment. The integration of algorithms revealed common factors contributing to Aβ accumulation prediction, paving the way for further refinements and broader applications in dementia research.

This revolutionary predictive model marks a significant leap forward in Alzheimer’s research, emphasizing the importance of innovative technologies in the quest for early detection and intervention. The intersection of machine learning, wearable devices, and medical data opens up new possibilities for addressing the challenges posed by neurodegenerative diseases.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment
2024-09-04
R&D
The Latest in Alzheimer’s Research: Restoring Cognitive Function with Nanotech, Gene Therapy, and Enhanced Brain Gamma Oscillations
2024-08-16
Alzheimer’s Drug LEQEMBI Approved for Treatment in Hong Kong
2024-07-12
LATEST
Generative AI Makes its Debut in Smart Healthcare with NVIDIA Experts at the Helm
2024-10-04
TCELS’s Path to a Self-Sufficient Biotech Thailand: Entrepreneurs in Global Competitiveness, Raw Material Exports, and Cosmetic Innovations
2024-10-04
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
Eyes on Nvidia: A Strong Investment Prospect, Driving Billions in AI Development and Advanced Infrastructure
2024-09-30
Immunai and AstraZeneca’s $18 Million AI Collaboration to Transform Cancer Drug Development
2024-09-26
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top